

Shahrokh F Shariat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5567447/publications.pdf>

Version: 2024-02-01

1,094
papers

59,210
citations

699

121
h-index

2736

192
g-index

1114
all docs

1114
docs citations

1114
times ranked

25028
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461.	0.9	1,594
2	Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 2013, 63, 234-241.	0.9	1,572
3	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. European Urology, 2013, 64, 639-653.	0.9	1,053
4	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	2.0	943
5	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	936
6	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 2015, 68, 868-879.	0.9	804
7	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	0.9	627
8	Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium. Journal of Urology, 2006, 176, 2414-2422.	0.2	613
9	Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2004, 291, 1325.	3.8	588
10	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	559
11	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	0.9	532
12	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 2016, 69, 300-310.	0.9	460
13	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 2102-2114.	13.9	427
14	European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology, 2013, 63, 1059-1071.	0.9	414
15	Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate, 2014, 74, 210-216.	1.2	352
16	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 2012, 62, 100-114.	0.9	349
17	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. European Urology, 2012, 61, 679-685.	0.9	345
18	Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors. Journal of Urology, 2003, 170, 1792-1797.	0.2	331

#	ARTICLE	IF	CITATIONS
19	Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy. <i>European Urology</i> , 2007, 51, 137-151.	0.9	307
20	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. <i>Journal of Urology</i> , 2013, 189, 1214-1221.	0.2	291
21	p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1014-1024.	0.8	290
22	Radical versus partial nephrectomy. <i>Cancer</i> , 2009, 115, 1465-1471.	2.0	285
23	Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6533-6539.	0.8	283
24	The effect of age and gender on bladder cancer: a critical review of the literature. <i>BJU International</i> , 2010, 105, 300-308.	1.3	281
25	Predicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 1844-1849.	0.2	277
26	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
27	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014, 113, 11-23.	1.3	274
28	Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review. <i>European Urology</i> , 2011, 60, 644-661.	0.9	272
29	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 612-618.	0.8	260
30	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 379-387.	1.2	260
31	Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature. <i>Clinical Cancer Research</i> , 2008, 14, 4400-4407.	3.2	252
32	An updated catalog of prostate cancer predictive tools. <i>Cancer</i> , 2008, 113, 3075-3099.	2.0	238
33	Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 61, 961-971.	0.9	238
34	Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. <i>Urology</i> , 2001, 58, 1008-1015.	0.5	235
35	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	0.9	235
36	Stage Specific Lymph Node Metastasis Mapping in Radical Cystectomy Specimens. <i>Journal of Urology</i> , 2004, 171, 1830-1834.	0.2	226

#	ARTICLE	IF	CITATIONS
37	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	0.9	225
38	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. <i>Cancer Epidemiology</i> , 2013, 37, 219-225.	0.8	222
39	Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2010, 184, 69-73.	0.2	221
40	Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. <i>Clinical Cancer Research</i> , 2006, 12, 6663-6676.	3.2	219
41	A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 67, 1122-1133.	0.9	218
42	Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. <i>European Urology</i> , 2016, 70, 1052-1068.	0.9	215
43	The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3573-3579.	0.8	211
44	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	0.9	211
45	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 925-933.	0.9	209
46	A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3576-3581.	0.8	205
47	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	0.9	205
48	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	0.9	201
49	Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. <i>Journal of Urology</i> , 2009, 182, 900-906.	0.2	200
50	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. <i>Lancet Oncology</i> , The, 2007, 8, 128-136.	5.1	198
51	Challenges of Cancer Biomarker Profiling. <i>European Urology</i> , 2007, 52, 1601-1609.	0.9	198
52	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	0.9	198
53	Association of the Circulating Levels of the Urokinase System of Plasminogen Activation With the Presence of Prostate Cancer and Invasion, Progression, and Metastasis. <i>Journal of Clinical Oncology</i> , 2007, 25, 349-355.	0.8	196
54	Urinary cytology has a poor performance for predicting invasive or high-grade upper tract urothelial carcinoma. <i>BJU International</i> , 2011, 108, 701-705.	1.3	195

#	ARTICLE	IF	CITATIONS
55	Impact of gender on bladder cancer incidence, staging, and prognosis. World Journal of Urology, 2011, 29, 457-463.	1.2	194
56	Hexyl Aminolevulinateâ€“Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Nonâ€“Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. European Urology, 2013, 64, 624-638.	0.9	193
57	Prognostic Factors and Risk Groups in T1G3 Nonâ€“Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-GuÃ©rin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	0.9	190
58	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2012, 61, 818-825.	0.9	188
59	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. Journal of Urology, 2009, 181, 2482-2489.	0.2	186
60	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. Journal of Urology, 2010, 183, 2165-2170.	0.2	186
61	Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2006, 176, 1354-1362.	0.2	185
62	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 2008, 112, 315-325.	2.0	185
63	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU International, 2011, 107, 898-904.	1.3	184
64	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2010, 184, 453-458.	0.2	182
65	Urine Markers for Detection and Surveillance of Nonâ€“Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	0.9	176
66	Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. European Urology, 2011, 60, 205-210.	0.9	175
67	Bladder cancer in the elderly. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 653-667.	0.8	174
68	A Systematic Review of the Volumeâ€“Outcome Relationship for Radical Prostatectomy. European Urology, 2013, 64, 786-798.	0.9	172
69	Urine Detection of Survivin is a Sensitive Marker for the Noninvasive Diagnosis of Bladder Cancer. Journal of Urology, 2004, 171, 626-630.	0.2	169
70	Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract: An International Validation Study. European Urology, 2010, 57, 1064-1071.	0.9	169
71	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. European Urology, 2012, 61, 245-253.	0.9	168
72	Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. Cancer Research, 2011, 71, 7376-7386.	0.4	166

#	ARTICLE	IF	CITATIONS
73	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU International, 2012, 109, 77-82.	1.3	164
74	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	0.9	163
75	Critical review of prostate cancer predictive tools. Future Oncology, 2009, 5, 1555-1584.	1.1	162
76	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. European Urology, 2009, 56, 1-9.	0.9	161
77	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU International, 2009, 103, 307-311.	1.3	160
78	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. European Urology, 2010, 57, 300-309.	0.9	159
79	The Effect of Tumor Location on Prognosis in Patients Treated with Radical Nephroureterectomy at Memorial Sloan-Kettering Cancer Center. European Urology, 2010, 58, 574-580.	0.9	159
80	A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. European Urology, 2011, 59, 88-95.	0.9	159
81	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. European Urology, 2014, 65, 742-754.	0.9	159
82	Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer, 2004, 100, 751-757.	2.0	158
83	Venous Thromboembolism After Major Cancer Surgery. JAMA Surgery, 2014, 149, 43.	2.2	158
84	Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2006, 175, 2048-2053.	0.2	157
85	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	0.9	156
86	NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 2005, 173, 1518-1525.	0.2	155
87	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	0.9	155
88	Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. European Urology, 2007, 51, 699-708.	0.9	154
89	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	0.9	154
90	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. European Journal of Cancer, 2013, 49, 1889-1897.	1.3	154

#	ARTICLE	IF	CITATIONS
91	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 854-855.	0.9	152
92	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. <i>Journal of Urology</i> , 2013, 189, 1662-1669.	0.2	152
93	Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. <i>European Journal of Cancer</i> , 2009, 45, 3291-3297.	1.3	151
94	Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2011, 29, 481-486.	1.2	149
95	Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus. <i>Urologia Internationalis</i> , 2015, 94, 1-24.	0.6	149
96	Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. <i>European Urology</i> , 2006, 50, 1254-1262.	0.9	147
97	Characteristics and clinical significance of histological variants of bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 651-668.	1.9	147
98	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 68-75.	0.2	146
99	Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. <i>BJU International</i> , 2006, 97, 997-1001.	1.3	144
100	Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease. <i>Clinical Cancer Research</i> , 2006, 12, 7369-7373.	3.2	144
101	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	3.0	144
102	A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2010, 75, 118-124.	0.5	144
103	Tumor markers in prostate cancer I: Blood-based markers. <i>Acta Oncologica</i> , 2011, 50, 61-75.	0.8	144
104	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. <i>European Urology</i> , 2009, 56, 512-519.	0.9	143
105	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. <i>Cancer</i> , 2007, 109, 1106-1113.	2.0	140
106	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019, 10, 2977.	5.8	140
107	Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. <i>European Urology</i> , 2011, 60, 776-783.	0.9	135
108	Comparison of stage migration patterns between Europe and the USA: an analysis of 11,350 men treated with radical prostatectomy for prostate cancer. <i>BJU International</i> , 2008, 101, 1513-1518.	1.3	134

#	ARTICLE	IF	CITATIONS
109	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	0.9	134
110	The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2010, 16, 4461-4467.	3.2	133
111	Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 687-700.	0.9	132
112	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010, 105, 1402-1412.	1.3	132
113	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
114	Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. <i>Prostate</i> , 2007, 67, 614-622.	1.2	131
115	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 70-77.	0.2	131
116	Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 481-487.	0.2	130
117	Clinicians are poor raters of life expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. <i>BJU International</i> , 2007, 100, 1254-1258.	1.3	129
118	Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. <i>European Urology</i> , 2012, 62, 696-703.	0.9	129
119	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. <i>Modern Pathology</i> , 2007, 20, 445-459.	2.9	128
120	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	1.3	128
121	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. <i>BJU International</i> , 2006, 98, 329-334.	1.3	126
122	What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.	1.6	126
123	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
124	A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. <i>European Urology</i> , 2012, 61, 725-731.	0.9	124
125	PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 1999, 161, 139-143.	0.2	121
126	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	0.9	121

#	ARTICLE	IF	CITATIONS
127	Statistical consideration for clinical biomarker research in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 389-400.	0.8	119
128	Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology, 2003, 61, 1140-1145.	0.5	116
129	Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma. Journal of Urology, 2013, 190, 1999-2004.	0.2	116
130	Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU International, 2010, 105, 1672-1677.	1.3	115
131	Improved Detection of Clinically Significant, Curable Prostate Cancer With Systematic 12-Core Biopsy. Journal of Urology, 2004, 171, 1089-1092.	0.2	114
132	Lymphovascular Invasion is a Pathological Feature of Biologically Aggressive Disease in Patients Treated With Radical Prostatectomy. Journal of Urology, 2004, 171, 1122-1127.	0.2	114
133	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.2	114
134	Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy. Journal of Clinical Oncology, 2004, 22, 1655-1663.	0.8	113
135	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	3.2	112
136	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". European Urology Focus, 2019, 5, 457-466.	1.6	112
137	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology, 2020, 78, 893-906.	0.9	112
138	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU International, 2011, 108, 24-30.	1.3	111
139	The impact of retransurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU International, 2016, 118, 44-52.	1.3	110
140	E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUP. Journal of Urology, 2001, 165, 1473-1479.	0.2	109
141	Can nomograms be superior to other prediction tools?. BJU International, 2009, 103, 492-497.	1.3	108
142	A Review of Integrated Staging Systems for Renal Cell Carcinoma. European Urology, 2012, 62, 303-314.	0.9	108
143	Location of the Primary Tumor is Not an Independent Predictor of Cancer Specific Mortality in Patients With Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2009, 182, 2177-2181.	0.2	106
144	Gender-related Differences in Patients With Stage I to III Upper Tract Urothelial Carcinoma: Results From the Surveillance, Epidemiology, and End Results Database. Urology, 2010, 75, 321-327.	0.5	106

#	ARTICLE	IF	CITATIONS
145	Predictors of Prostate Cancer After Initial Negative Systematic 12 Core Biopsy. Journal of Urology, 2004, 171, 1850-1854.	0.2	105
146	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. European Urology, 2013, 63, 724-732.	0.9	105
147	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 543-557.	0.9	105
148	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. European Urology, 2014, 66, 913-919.	0.9	103
149	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. European Urology Focus, 2019, 5, 205-223.	1.6	103
150	Segmental Ureterectomy Can Safely be Performed in Patients With Transitional Cell Carcinoma of the Ureter. Journal of Urology, 2010, 183, 1324-1329.	0.2	102
151	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	0.9	102
152	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	0.9	101
153	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. European Urology, 2019, 75, 176-183.	0.9	101
154	Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer. Journal of Urology, 2006, 176, 919-926.	0.2	100
155	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	0.9	100
156	Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1063-1072.	3.3	100
157	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 755-765.	2.6	100
158	Comparison Between Laparoscopic and Open Radical Nephroureterectomy in a Contemporary Group of Patients: Are Recurrence and Disease-Specific Survival Associated with Surgical Technique?. European Urology, 2010, 58, 645-651.	0.9	98
159	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	0.9	98
160	Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU International, 2017, 120, 313-319.	1.3	98
161	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. European Urology, 2010, 58, 851-864.	0.9	96
162	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World Journal of Urology, 2018, 36, 1981-1995.	1.2	95

#	ARTICLE	IF	CITATIONS
163	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 441-448.	0.8	94
164	Prognostic factors for upper urinary tract urothelial carcinoma. Nature Reviews Urology, 2011, 8, 440-447.	1.9	94
165	Multifocal Carcinoma In Situ of the Upper Tract Is Associated With High Risk of Bladder Cancer Recurrence. European Urology, 2012, 61, 1069-1070.	0.9	94
166	Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 2045-2052.	1.2	94
167	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph node density. BJU International, 2009, 103, 302-306.	1.3	93
168	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. Journal of Urology, 2009, 182, 78-84.	0.2	93
169	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 342-348.	0.4	93
170	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	0.9	93
171	Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology, 2008, 26, 59-65.	1.2	92
172	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. Journal of Urology, 2010, 183, 1744-1750.	0.2	91
173	Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). European Urology, 2013, 64, 472-477.	0.9	91
174	Urine markers for detection and surveillance of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 222-229.	0.8	91
175	Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World Journal of Urology, 2018, 36, 157-170.	1.2	91
176	A delay in radical nephroureterectomy can lead to upstaging. BJU International, 2010, 105, 812-817.	1.3	90
177	Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU International, 2012, 110, E7-13.	1.3	90
178	Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. World Journal of Urology, 2015, 33, 563-570.	1.2	90
179	A population-based competing risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011, 117, 103-109.	2.0	89
180	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Human Pathology, 2006, 37, 1568-1576.	1.1	88

#	ARTICLE	IF	CITATIONS
181	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 252-258.	0.8	88
182	Head-to-head comparison of PI-RADS v2 and PI-RADS v1. European Journal of Radiology, 2016, 85, 1125-1131.	1.2	88
183	Nomograms for Bladder Cancer. European Urology, 2008, 54, 41-53.	0.9	87
184	Systematic Review and Meta-Analysis of Perioperative and Oncologic Outcomes of Laparoscopic Cryoablation Versus Laparoscopic Partial Nephrectomy for the Treatment of Small Renal Tumors. Journal of Urology, 2014, 191, 1209-1217.	0.2	87
185	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2011, 185, 456-461.	0.2	86
186	Molecular markers in bladder cancer. World Journal of Urology, 2019, 37, 31-40.	1.2	86
187	Should Bladder Cuff Excision Remain the Standard of Care at Nephroureterectomy in Patients with Urothelial Carcinoma of the Renal Pelvis? A Population-based Study. European Urology, 2010, 57, 956-962.	0.9	84
188	Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU International, 2011, 108, 406-412.	1.3	84
189	E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology, 2001, 57, 60-65.	0.5	83
190	Preoperative plasma levels of transforming growth factor γ 1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer, 2001, 92, 2985-2992.	2.0	82
191	Cyclooxygenase-2 is Highly Expressed in Carcinoma in Situ and T1 Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2003, 169, 938-942.	0.2	82
192	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	0.5	82
193	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. Journal of Urology, 2017, 197, 1419-1426.	0.2	82
194	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. European Urology, 2019, 75, 649-658.	0.9	82
195	PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. Journal of Urology, 2002, 167, 1475-1481.	0.2	80
196	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 904-908.	0.8	80
197	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European Urology Focus, 2015, 1, 17-27.	1.6	80
198	Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers. Clinical Cancer Research, 2008, 14, 3785-3791.	3.2	79

#	ARTICLE	IF	CITATIONS
199	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. <i>Nature Reviews Urology</i> , 2016, 13, 471-479.	1.9	79
200	Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. <i>Urology</i> , 2000, 56, 735-740.	0.5	78
201	Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 27-32.	0.8	78
202	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
203	Gender differences in incidence and outcomes of urothelial and kidney cancer. <i>Nature Reviews Urology</i> , 2015, 12, 585-592.	1.9	78
204	Partial Cystectomy Does Not Undermine Cancer Control in Appropriately Selected Patients With Urothelial Carcinoma of the Bladder: A Population-based Matched Analysis. <i>Urology</i> , 2009, 74, 858-864.	0.5	77
205	Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. <i>BJU International</i> , 2010, 106, 1216-1222.	1.3	77
206	Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. <i>World Journal of Urology</i> , 2011, 29, 487-494.	1.2	77
207	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	1.3	77
208	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	0.9	77
209	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 507-514.	1.2	77
210	Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. <i>Human Pathology</i> , 2007, 38, 1703-1713.	1.1	76
211	Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy. <i>European Urology</i> , 2007, 51, 152-160.	0.9	76
212	Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 179, 2164-2169.	0.2	75
213	Perioperative Mortality Is Significantly Greater in Septuagenarian and Octogenarian Patients Treated With Radical Cystectomy for Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2011, 77, 660-666.	0.5	74
214	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. <i>World Journal of Urology</i> , 2017, 35, 337-353.	1.2	74
215	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	1.6	74
216	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74

#	ARTICLE	IF	CITATIONS
217	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. <i>Urology</i> , 2009, 73, 142-146.	0.5	73
218	Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. <i>Cancer</i> , 2010, 116, 3774-3784.	2.0	73
219	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 716-723.	0.8	73
220	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 389-399.	0.8	72
221	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	1.6	72
222	Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2020, 38, 1165-1175.	1.2	72
223	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2011, 108, 1286-1291.	1.3	71
224	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 47-62.	0.8	71
225	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	1.2	71
226	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	71
227	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. <i>European Urology</i> , 2014, 66, 561-568.	0.9	70
228	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. <i>Clinical Cancer Research</i> , 2009, 15, 7012-7019.	3.2	69
229	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	1.3	69
230	Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients. <i>Journal of Urology</i> , 2010, 183, 1757-1763.	0.2	69
231	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	0.9	69
232	Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma – results from a comprehensive multi-centre database (CORONA/SATURN-P<project). <i>BJU International</i> , 2013, 112, 909-916.	1.3	69
233	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.2	69
234	Molecular markers in bladder cancer. <i>Current Opinion in Urology</i> , 2008, 18, 1-8.	0.9	68

#	ARTICLE	IF	CITATIONS
235	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. <i>European Urology</i> , 2013, 64, 465-471.	0.9	68
236	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. <i>BJU International</i> , 2009, 103, 1359-1362.	1.3	67
237	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , 2013, 111, 249-255.	1.3	67
238	Obesity is Associated with Worse Outcomes in Patients with T1 High Grade Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2013, 190, 480-486.	0.2	66
239	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 335-341.	0.8	66
240	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 403-410.	2.6	66
241	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. <i>European Urology</i> , 2020, 78, 209-220.	0.9	66
242	Correlation of Cyclooxygenase-2 Expression With Molecular Markers, Pathological Features and Clinical Outcome of Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 170, 985-989.	0.2	65
243	Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. <i>European Urology</i> , 2012, 61, 715-721.	0.9	65
244	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. <i>Journal of Urology</i> , 2010, 184, 888-894.	0.2	64
245	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. <i>International Journal of Urology</i> , 2012, 19, 1060-1066.	0.5	64
246	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. <i>BJU International</i> , 2012, 109, 1147-1154.	1.3	64
247	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. <i>European Urology</i> , 2013, 63, 1049-1058.	0.9	64
248	Critical evaluation of urinary markers for bladder cancer detection and monitoring. <i>Reviews in Urology</i> , 2008, 10, 120-35.	0.9	64
249	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 959-967.	1.3	63
250	Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy. <i>Urology</i> , 2008, 71, 302-307.	0.5	62
251	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. <i>World Journal of Urology</i> , 2011, 29, 473-480.	1.2	62
252	Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 666-672.	0.8	62

#	ARTICLE	IF	CITATIONS
253	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. <i>European Urology</i> , 2013, 64, 266-276.	0.9	62
254	Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. <i>BJU International</i> , 2014, 114, 733-740.	1.3	62
255	Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. <i>Urology</i> , 2003, 61, 1053-1058.	0.5	61
256	Development and Split-Sample Validation of a Nomogram Predicting the Probability of Seminal Vesicle Invasion at Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 98-105.	0.9	61
257	Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 5680-5687.	2.0	61
258	Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. <i>BJU International</i> , 2009, 103, 1368-1374.	1.3	61
259	Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality. <i>Urology</i> , 2010, 75, 376-381.	0.5	61
260	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	0.9	61
261	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61
262	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. <i>European Urology</i> , 2021, 79, 44-53.	0.9	61
263	Thirty-Day Mortality After Nephrectomy: Clinical Implications for Informed Consent. <i>European Urology</i> , 2009, 56, 998-1005.	0.9	60
264	Obesity Adversely Impacts Disease Specific Outcomes in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2011, 186, 66-72.	0.2	60
265	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Current Urology Reports</i> , 2014, 15, 404.	1.0	60
266	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	0.9	60
267	Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients. <i>European Urology</i> , 2009, 55, 1124-1134.	0.9	59
268	Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2013, 112, 1105-1112.	1.3	59
269	A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. <i>BJU International</i> , 2007, 100, 1015-1020.	1.3	58
270	Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. <i>Urology</i> , 2009, 74, 1070-1074.	0.5	58

#	ARTICLE	IF	CITATIONS
271	Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. <i>Journal of Urology</i> , 2010, 183, 87-93.	0.2	58
272	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.2	58
273	Predictive value of expression of transforming growth factor- β 1 and its receptors in transitional cell carcinoma of the urinary bladder. <i>Cancer</i> , 2001, 92, 1475-1483.	2.0	57
274	Estrogen and Progesterone Hormonal Receptor Expression in Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2009, 56, 1093-1095.	0.9	57
275	Association of Tumor Necrosis With Pathological Features and Clinical Outcome in 754 Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An International Validation Study. <i>Journal of Urology</i> , 2010, 184, 1895-1900.	0.2	57
276	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 187, 845-851.	0.2	57
277	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>European Urology</i> , 2019, 75, 319-328.	0.9	57
278	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 68.e1-68.e7.	0.8	56
279	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	2.0	56
280	Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. <i>Cancer Research</i> , 2003, 63, 4662-70.	0.4	56
281	New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. <i>BJU International</i> , 2008, 101, 675-683.	1.3	55
282	Mortality and Morbidity After Cyto-reductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 2988-2996.	0.7	55
283	No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. <i>World Journal of Urology</i> , 2011, 29, 465-472.	1.2	55
284	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. <i>World Journal of Urology</i> , 2013, 31, 1029-1036.	1.2	55
285	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978.	0.5	55
286	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage $\leq T_1$ disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013, 111, 1215-1221.	1.3	55
287	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e9-47.e14.	0.8	55
288	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 445-452.	0.9	55

#	ARTICLE	IF	CITATIONS
289	Soluble Fas α A promising novel urinary marker for the detection of recurrent superficial bladder cancer. <i>Cancer</i> , 2006, 106, 1701-1707.	2.0	54
290	Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Urology</i> , 2007, 70, 482-486.	0.5	54
291	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 907-913.	0.2	54
292	Comparison of partial vs radical nephrectomy with regard to other α cause mortality in T1 renal cell carcinoma among patients aged \geq 75 years with multiple comorbidities. <i>BJU International</i> , 2013, 111, 67-73.	1.3	54
293	Impact of peri α operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>BJU International</i> , 2014, 113, 393-398.	1.3	54
294	Prognostic significance of markers of systemic inflammatory response in patients with non α muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 483.e17-483.e24.	0.8	54
295	Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. <i>World Journal of Urology</i> , 2018, 36, 1019-1029.	1.2	54
296	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non α muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non α muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	2.6	54
297	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	0.7	53
298	Marital status: a gender α independent risk factor for poorer survival after radical cystectomy. <i>BJU International</i> , 2012, 110, 1301-1309.	1.3	53
299	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non α muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	0.8	53
300	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. <i>European Urology Oncology</i> , 2018, 1, 46-53.	2.6	53
301	Differences in trends in the use of robot α ssisted and open radical cystectomy and changes over time in peri α operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
302	Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein. <i>Journal of Clinical Oncology</i> , 2003, 21, 1223-1231.	0.8	52
303	Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 182, 2607-2612.	0.2	52
304	Female with bladder cancer: what and why is there a difference?. <i>Translational Andrology and Urology</i> , 2016, 5, 668-682.	0.6	52
305	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. <i>European Urology</i> , 2010, 58, 112-117.	0.9	51
306	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , 2011, 18, 616-629.	0.5	51

#	ARTICLE	IF	CITATIONS
307	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Nonâ€“Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 59, 1026-1031.	0.9	51
308	The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. <i>Cancer Causes and Control</i> , 2011, 22, 1085-1095.	0.8	51
309	Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscleâ€“invasive bladder cancer and negative cytology. <i>Cancer</i> , 2011, 117, 2892-2897.	2.0	51
310	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	1.0	51
311	External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. <i>Prostate</i> , 2013, 73, 211-218.	1.2	51
312	In-hospital Mortality and Failure to Rescue After Cyto-reductive Nephrectomy. <i>European Urology</i> , 2013, 63, 1107-1114.	0.9	51
313	Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017, 35, 535-548.	1.2	51
314	Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 953.	3.4	51
315	EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2005, 174, 2046-2050.	0.2	50
316	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. <i>World Journal of Urology</i> , 2011, 29, 495-501.	1.2	50
317	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2012, 48, 1503-1511.	1.3	50
318	Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. <i>International Journal of Urology</i> , 2012, 19, 645-651.	0.5	50
319	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 949-956.	0.9	50
320	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 430-436.	0.8	50
321	Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. <i>BJU International</i> , 2014, 114, 674-679.	1.3	49
322	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2014, 191, 316-322.	0.2	49
323	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmetteâ€“GuÃ©rin after transurethral resection of the bladder tumor. <i>World Journal of Urology</i> , 2020, 38, 143-150.	1.2	49
324	Response assessment using [⁶⁸ Ga]Gaâ€“PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationâ€“resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	1.2	49

#	ARTICLE	IF	CITATIONS
325	Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series. Journal of Urology, 2010, 184, 74-80.	0.2	48
326	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU International, 2013, 111, 404-411.	1.3	48
327	Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. European Journal of Radiology, 2014, 83, 909-913.	1.2	48
328	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e1-21.e9.	0.8	48
329	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	1.6	48
330	Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective. Nature Reviews Urology, 2022, 19, 280-294.	1.9	48
331	Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. Urology, 2009, 74, 373-377.	0.5	47
332	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	0.9	47
333	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncology, 2020, 16, 507-516.	1.1	47
334	Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. Journal of Surgical Oncology, 2017, 115, 455-461.	0.8	46
335	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	2.6	46
336	Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 713-720.	3.3	46
337	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. Journal of Geriatric Oncology, 2020, 11, 1043-1053.	0.5	46
338	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. European Urology, 2021, 79, 783-792.	0.9	46
339	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2012, 188, 2120-2128.	0.2	45
340	Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1a-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors?. European Urology, 2015, 67, 943-951.	0.9	45
341	A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU International, 2019, 123, 11-21.	1.3	45
342	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1892-1900.	1.0	45

#	ARTICLE	IF	CITATIONS
343	Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder. <i>Journal of Urology</i> , 2007, 177, 1163-1168.	0.2	44
344	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. <i>International Journal of Cancer</i> , 2007, 121, 791-795.	2.3	44
345	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. <i>BJU International</i> , 2011, 108, E304-E309.	1.3	44
346	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. <i>European Urology</i> , 2012, 62, 224-231.	0.9	44
347	Survival after radical cystectomy of non- <i>Chilharzial</i> squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. <i>BJU International</i> , 2012, 109, 564-569.	1.3	44
348	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. <i>Biomolecules</i> , 2016, 6, 37.	1.8	44
349	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273.	2.0	44
350	Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 468-475.	0.8	43
351	Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study. <i>Urology</i> , 2008, 72, 1090-1095.	0.5	43
352	Use of Preoperative Plasma Endoglin for Prediction of Lymph Node Metastasis in Patients with Clinically Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1418-1422.	3.2	43
353	A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis. <i>European Urology</i> , 2011, 60, 1152-1159.	0.9	43
354	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. <i>Journal of Urology</i> , 2012, 187, 457-462.	0.2	43
355	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e19-65.e25.	0.8	43
356	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. <i>Translational Andrology and Urology</i> , 2016, 5, 735-744.	0.6	43
357	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. <i>Journal of Urology</i> , 2017, 197, 287-295.	0.2	43
358	Immunocytology Is a Strong Predictor of Bladder Cancer Presence in Patients With Painless Hematuria: A Multicentre Study. <i>European Urology</i> , 2012, 61, 185-192.	0.9	42
359	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. <i>Canadian Urological Association Journal</i> , 2014, 8, 695.	0.3	42
360	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1166-1171.	0.8	42

#	ARTICLE	IF	CITATIONS
361	Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1078-1087.	0.8	42
362	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1081-1089.	0.6	42
363	The changing role of lasers in urologic surgery. <i>Current Opinion in Urology</i> , 2020, 30, 24-29.	0.9	42
364	Risk Stratification for Bladder Tumor Recurrence, Stage and Grade by Urinary Nuclear Matrix Protein 22 and Cytology. <i>European Urology</i> , 2004, 45, 304-313.	0.9	41
365	Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2008, 14, 3362-3366.	3.2	41
366	Sex Disparities in Cancer Mortality: The Risks of Being a Man in the United States. <i>Journal of Urology</i> , 2013, 189, 1470-1474.	0.2	41
367	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2014, 114, 56-61.	1.3	41
368	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 1541-1547.	1.2	41
369	A urinary microRNA (miR) signature for diagnosis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e1-531.e8.	0.8	41
370	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. <i>Journal of Endourology</i> , 2019, 33, 438-447.	1.1	41
371	Survival after Cyto-reductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019, 5, 488-496.	1.6	41
372	Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. <i>Prostate</i> , 2009, 69, 886-894.	1.2	40
373	Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. <i>BJU International</i> , 2012, 109, 1155-1161.	1.3	40
374	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.2	40
375	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	1.2	40
376	A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 293-305.	0.8	40
377	En bloc resection for nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 41-47.	0.9	40
378	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 583-598.	0.9	40

#	ARTICLE	IF	CITATIONS
379	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 792-801.	2.6	40
380	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	2.6	40
381	Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. <i>Urology</i> , 2000, 56, 423-429.	0.5	39
382	Prognostic Value of Microvascular Invasion in Predicting the Cancer Specific Survival and Risk of Metastatic Disease in Renal Cell Carcinoma: A Multicenter Investigation. <i>Journal of Urology</i> , 2012, 187, 418-423.	0.2	39
383	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 5-11.	1.2	39
384	Pathological Features of Lymph Node Metastasis for Predicting Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 1314-1319.	0.2	39
385	Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. <i>World Journal of Urology</i> , 2015, 33, 105-110.	1.2	39
386	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016, 2, 79-85.	1.6	39
387	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. <i>Surgical Oncology</i> , 2020, 32, 8-13.	0.8	39
388	Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes: a Systematic Review and Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 595-600.	0.5	39
389	Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. <i>Urology</i> , 2013, 82, 1323-1329.	0.5	38
390	Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. <i>BJU International</i> , 2014, 113, 70-76.	1.3	38
391	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	0.8	38
392	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493.	0.2	38
393	Clinicians are Most Familiar with Nomograms and Rate their Clinical Usefulness Highest, Look-up Tables are Second Best. <i>European Urology</i> , 2008, 54, 958-959.	0.9	37
394	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
395	First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). <i>Journal of Clinical Oncology</i> , 2021, 39, 391-391.	0.8	37
396	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. <i>BJU International</i> , 2022, 129, 423-433.	1.3	37

#	ARTICLE	IF	CITATIONS
397	Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. <i>BJU International</i> , 2011, 108, 526-530.	1.3	36
398	Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 309-317.	0.7	36
399	The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. <i>World Journal of Urology</i> , 2014, 32, 669-676.	1.2	36
400	Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. <i>World Journal of Urology</i> , 2014, 32, 999-1005.	1.2	36
401	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017, 49, 2143-2149.	0.6	36
402	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e17-8.e24.	0.8	36
403	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	0.9	36
404	C: IGF-I IGFBP-3 I. <i>Urology</i> , 2003, 61, 359-364.	0.5	35
405	Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. <i>Journal of Urology</i> , 2010, 184, 464-469.	0.2	35
406	Annual Surgical Caseload and Open Radical Prostatectomy Outcomes: Improving Temporal Trends. <i>Journal of Urology</i> , 2010, 184, 2285-2290.	0.2	35
407	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.2	35
408	Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2014, 65, 201-209.	0.9	35
409	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	0.2	35
410	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e123-e130.	0.9	35
411	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.2	35
412	Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. <i>BJU International</i> , 2019, 123, 646-650.	1.3	35
413	Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. <i>BJU International</i> , 2008, 101, 1362-1367.	1.3	34
414	Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. <i>BJU International</i> , 2011, 108, 502-507.	1.3	34

#	ARTICLE	IF	CITATIONS
415	A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 439-446.	0.7	34
416	Conditional survival predictions after surgery for patients with penile carcinoma. <i>Cancer</i> , 2011, 117, 3723-3730.	2.0	34
417	Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 492-499.	0.9	34
418	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 29.e13-29.e20.	0.8	34
419	In-hospital length of stay after major surgical oncological procedures. <i>European Journal of Surgical Oncology</i> , 2018, 44, 969-974.	0.5	34
420	Current Disease Management of Primary Urethral Carcinoma. <i>European Urology Focus</i> , 2019, 5, 722-734.	1.6	34
421	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	0.9	34
422	Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. <i>Reviews in Urology</i> , 2004, 6, 58-72.	0.9	34
423	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. <i>BJU International</i> , 2007, 100, 528-532.	1.3	33
424	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. <i>Journal of Urology</i> , 2011, 186, 1849-1854.	0.2	33
425	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2012, 30, 753-759.	1.2	33
426	Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 1204-1206.	0.9	33
427	Conditional survival after nephrectomy for renal cell carcinoma (<sc>RCC</sc>): changes in future survival probability over time. <i>BJU International</i> , 2013, 111, E283-9.	1.3	33
428	Prognosis of patients with pelvic lymph node (<sc>LN</sc>) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest <sc>LN</sc> metastasis. <i>BJU International</i> , 2014, 114, 503-510.	1.3	33
429	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	0.8	33
430	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 251-259.	1.2	33
431	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. <i>Prostate</i> , 2017, 77, 686-693.	1.2	33
432	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e267-e273.	0.9	33

#	ARTICLE	IF	CITATIONS
433	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2018, 4, 91-112.	0.2	33
434	Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Urology</i> , 2019, 26, 760-774.	0.5	33
435	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>European Urology Focus</i> , 2020, 6, 1233-1239.	1.6	33
436	Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. <i>Journal of Urology</i> , 2002, 167, 1475-81.	0.2	33
437	A NOVEL INTRAURETHRAL PROSTATIC BRIDGE CATHETER FOR PREVENTION OF TEMPORARY PROSTATIC OBSTRUCTION FOLLOWING HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 1999, 161, 144-151.	0.2	32
438	Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy. <i>Journal of Urology</i> , 2011, 185, 1216-1221.	0.2	32
439	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 480-486.	0.8	32
440	Impact of Statin Use on Oncologic Outcomes in Patients with Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2013, 190, 487-492.	0.2	32
441	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. <i>World Journal of Urology</i> , 2018, 36, 231-240.	1.2	32
442	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , 2018, 121, 592-599.	1.3	32
443	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. <i>BJU International</i> , 2019, 124, 738-745.	1.3	32
444	Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 315-333.	0.8	32
445	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32
446	Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer. <i>Therapeutic Advances in Urology</i> , 2009, 1, 13-26.	0.9	31
447	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2011, 77, 861-866.	0.5	31
448	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	1.3	31
449	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	0.8	31
450	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , 2019, 2, 541-548.	2.6	31

#	ARTICLE	IF	CITATIONS
451	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1037-1054.	1.0	31
452	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	1.6	31
453	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , 2012, 109, 685-690.	1.3	30
454	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. <i>Cancer Biology and Therapy</i> , 2014, 15, 1239-1247.	1.5	30
455	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016, 195, 1354-1361.	0.2	30
456	Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 264-271.	0.8	30
457	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT ₂₋₃ non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	1.3	30
458	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2169-2177.	3.3	30
459	Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 1-10.	2.0	30
460	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. <i>Urology</i> , 2006, 68, 538-542.	0.5	29
461	Accuracy of Life Tables in Predicting Overall Survival in Candidates for Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 88-94.	0.4	29
462	Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. <i>BJU International</i> , 2012, 109, 1807-1812.	1.3	29
463	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.2	29
464	Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer. <i>European Urology</i> , 2015, 68, 552-554.	0.9	29
465	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	1.3	29
466	Prediction of cancer-specific survival after radical cystectomy in pT _{4a} urothelial carcinoma of the bladder: development of a tool for clinical decision-making. <i>BJU International</i> , 2016, 117, 272-279.	1.3	29
467	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
468	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e755-e764.	0.9	29

#	ARTICLE	IF	CITATIONS
469	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. <i>World Journal of Urology</i> , 2018, 36, 1621-1627.	1.2	29
470	3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. <i>European Radiology</i> , 2018, 28, 1634-1641.	2.3	29
471	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	2.6	29
472	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
473	Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. <i>Cancer Research</i> , 2003, 63, 5874-8.	0.4	29
474	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011, 108, 687-692.	1.3	28
475	In-hospital mortality and failure-to-rescue rates after radical cystectomy. <i>BJU International</i> , 2013, 112, E20-7.	1.3	28
476	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. <i>BJU International</i> , 2014, 113, 911-917.	1.3	28
477	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [¹¹ C]acetate PET as a prognostic marker. <i>Prostate</i> , 2015, 75, 1760-1767.	1.2	28
478	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
479	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentaecta. <i>World Journal of Urology</i> , 2015, 33, 1945-1950.	1.2	28
480	Role of salvage lymph node dissection in prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 581-589.	0.9	28
481	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1â€2 NO M0 renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 1899-1905.	1.2	28
482	Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e1-239.e7.	0.8	28
483	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. <i>Journal of Urology</i> , 2018, 199, 1149-1157.	0.2	28
484	Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 637-646.	0.8	28
485	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
486	Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. <i>BJU International</i> , 2008, 101, 561-565.	1.3	27

#	ARTICLE	IF	CITATIONS
487	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	0.9	27
488	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e603-e607.	0.9	27
489	Survival benefit of local versus no local treatment for metastatic prostate cancerâ€”Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	1.2	27
490	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 376-384.e1.	0.9	27
491	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	2.0	27
492	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 60-68.e1.	0.9	27
493	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	0.9	27
494	Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 16-22.	0.4	26
495	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	1.3	26
496	Effect of statin use on outcomes of nonâ€”muscleâ€”invasive bladder cancer. <i>BJU International</i> , 2013, 112, E4-12.	1.3	26
497	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	0.2	26
498	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e21-71.e26.	0.8	26
499	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e9-167.e16.	0.8	26
500	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017, 35, 327-335.	1.2	26
501	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. <i>BJU International</i> , 2017, 119, 268-275.	1.3	26
502	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 77.e1-77.e7.	0.8	26
503	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 774-782.	0.8	26
504	Bilharzial vs nonâ€”bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenaseâ€”2 expression. <i>BJU International</i> , 2011, 108, 31-37.	1.3	25

#	ARTICLE	IF	CITATIONS
505	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 31-36.	1.2	25
506	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1027-1034.	0.7	25
507	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	0.8	25
508	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. <i>Journal of Urology</i> , 2015, 194, 1456-1462.	0.2	25
509	Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. <i>Urologia Internationalis</i> , 2015, 94, 25-30.	0.6	25
510	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. <i>Urologia</i> , 2017, 84, 9-19.	0.3	25
511	The interaction of gender and smoking on bladder cancer risks. <i>Current Opinion in Urology</i> , 2019, 29, 249-255.	0.9	25
512	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019, 2, 355-364.	2.6	25
513	Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e19-179.e28.	0.8	25
514	Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 247-257.	1.0	25
515	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1459-1474.	1.0	25
516	International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. <i>BJU International</i> , 2012, 110, 674-681.	1.3	24
517	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. <i>BJU International</i> , 2013, 111, 589-595.	1.3	24
518	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	0.9	24
519	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 27.e7-27.e13.	0.8	24
520	Robotic assisted simple prostatectomy. <i>Current Opinion in Urology</i> , 2018, 28, 309-314.	0.9	24
521	Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 409-418.	0.9	24
522	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 372-379.	0.8	24

#	ARTICLE	IF	CITATIONS
523	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	1.3	24
524	Upper urinary tract disease: what we know today and unmet needs. <i>Translational Andrology and Urology</i> , 2015, 4, 261-72.	0.6	24
525	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. <i>Urology Annals</i> , 2011, 3, 119.	0.3	23
526	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <i>World Journal of Urology</i> , 2012, 30, 847-852.	1.2	23
527	Sociodemographic disparities in the treatment of small renal masses. <i>BJU International</i> , 2013, 111, E274-82.	1.3	23
528	Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?. <i>World Journal of Urology</i> , 2017, 35, 567-577.	1.2	23
529	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 43-46.	0.3	23
530	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 312.e9-312.e15.	0.8	23
531	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	1.2	23
532	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e130-e139.	0.9	23
533	Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. <i>World Journal of Urology</i> , 2020, 38, 1437-1449.	1.2	23
534	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	2.4	23
535	Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. <i>Journal of Urology</i> , 2007, 178, 1229-1237.	0.2	22
536	Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. <i>BJU International</i> , 2007, 101, 070915222359003-???	1.3	22
537	Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder†. <i>Human Pathology</i> , 2011, 42, 347-355.	1.1	22
538	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. <i>BJU International</i> , 2014, 113, 733-740.	1.3	22
539	Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 663-669.	0.8	22
540	Adjuvant cisplatin-based combined chemotherapy for lymph node (<sc>LN</sc>)–positive urothelial carcinoma of the bladder (<sc>UCB</sc>) after radical cystectomy (<sc>RC</sc>): a retrospective international study of >1500 patients. <i>BJU International</i> , 2015, 115, 722-727.	1.3	22

#	ARTICLE	IF	CITATIONS
541	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
542	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e1-233.e6.	0.8	22
543	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	1.2	22
544	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. <i>Urologia Internationalis</i> , 2018, 101, 7-15.	0.6	22
545	Validation of the Social Security Administration Life Tables (2004–2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	1.6	22
546	The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 46-53.	0.6	22
547	Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 88-94.e2.	0.9	22
548	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 76.e1-76.e9.	0.8	22
549	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 573-580.	2.0	22
550	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 117-124.	0.9	22
551	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	0.5	22
552	Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	1.2	22
553	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
554	Update on intravesical agents for non-muscle-invasive bladder cancer. <i>Immunotherapy</i> , 2010, 2, 381-392.	1.0	21
555	A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. <i>Prostate</i> , 2011, 71, 1587-1594.	1.2	21
556	Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?. <i>Therapeutic Advances in Urology</i> , 2011, 3, 69-80.	0.9	21
557	Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. <i>International Journal of Urology</i> , 2013, 20, 405-410.	0.5	21
558	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. <i>Canadian Urological Association Journal</i> , 2016, 10, 82.	0.3	21

#	ARTICLE	IF	CITATIONS
559	The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 659-671.	0.8	21
560	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1238-1245.	0.5	21
561	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019, 5, 467-473.	1.6	21
562	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 718-723.	0.5	21
563	Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. <i>World Journal of Urology</i> , 2021, 39, 3707-3709.	1.2	21
564	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	3.3	21
565	Prognostic role of the systemic immuneâinflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	2.0	21
566	Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. <i>European Urology Focus</i> , 2020, 6, 170-177.	1.6	21
567	Survival after nephroureterectomy for upper tract urothelial carcinoma: A populationâbased competingârisks analysis. <i>International Journal of Urology</i> , 2014, 21, 249-256.	0.5	20
568	Trimodal therapy for invasive bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 476-482.	0.9	20
569	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2015, 33, 1165-1171.	1.2	20
570	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e7-256.e13.	0.8	20
571	Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. <i>Investigative Radiology</i> , 2018, 53, 736-741.	3.5	20
572	Contemporary conditional cancerâspecific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. <i>Journal of Surgical Oncology</i> , 2020, 121, 1154-1161.	0.8	20
573	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	2.4	20
574	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 95.e1-95.e6.	0.9	20
575	Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. <i>BJU International</i> , 2008, 101, 1356-1361.	1.3	19
576	Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery. <i>Urologia Internationalis</i> , 2011, 87, 42-48.	0.6	19

#	ARTICLE	IF	CITATIONS
577	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
578	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. <i>Urology</i> , 2016, 95, 132-138.	0.5	19
579	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of nonâ€“muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	0.8	19
580	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 283-289.	0.2	19
581	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	0.8	19
582	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , 2018, 1, 314-320.	2.6	19
583	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 693-696.	0.9	19
584	Prognostic Value of Serum Cholinesterase in Nonâ€“muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1123-e1132.	0.9	19
585	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1026-e1035.	0.9	19
586	Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 78-87.	0.9	19
587	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 580-593.	2.6	19
588	Preoperative frailty predicts adverse shortâ€“term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 688-696.	0.8	19
589	Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. <i>Archivos Espanoles De Urologia</i> , 2011, 64, 681-94.	0.1	19
590	Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. <i>Urology Journal</i> , 2014, 11, 1435-41.	0.3	19
591	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	0.5	18
592	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1141-1150.	0.8	18
593	Kidney-sparing surgery for upper tract urothelial cancer. <i>Current Opinion in Urology</i> , 2015, 25, 100-104.	0.9	18
594	How to optimally manage elderly bladder cancer patients?. <i>Translational Andrology and Urology</i> , 2016, 5, 683-691.	0.6	18

#	ARTICLE	IF	CITATIONS
595	The treatment of muscle-invasive bladder cancer in geriatric patients. <i>Current Opinion in Urology</i> , 2016, 26, 160-164.	0.9	18
596	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2018, 36, 639-644.	1.2	18
597	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e17-81.e24.	0.8	18
598	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , 2018, 28, 570-576.	0.9	18
599	The impact of moderate wine consumption on the risk of developing prostate cancer. <i>Clinical Epidemiology</i> , 2018, Volume 10, 431-444.	1.5	18
600	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. <i>Surgical Oncology</i> , 2019, 28, 201-207.	0.8	18
601	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
602	Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 20-25.e2.	0.9	18
603	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	1.2	18
604	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	1.2	18
605	Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. <i>European Urology Oncology</i> , 2022, 5, 505-516.	2.6	18
606	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. <i>Cancer</i> , 2012, 118, 4991-4998.	2.0	17
607	Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 62, e27-e29.	0.9	17
608	Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). <i>BJU International</i> , 2014, 113, E62-6.	1.3	17
609	Diagnosis and Management of Upper Tract Urothelial Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 271-288.	0.9	17
610	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 533.e1-533.e10.	0.8	17
611	Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1429-1436.	1.2	17
612	The Moreau Strain of Bacillus Calmette-Guérin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?. <i>Urologia Internationalis</i> , 2016, 96, 46-50.	0.6	17

#	ARTICLE	IF	CITATIONS
613	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 425-438.	1.3	17
614	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. Anticancer Research, 2019, 39, 4357-4361.	0.5	17
615	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e602-e611.	0.9	17
616	Smoking and bladder cancer: review of the recent literature. Current Opinion in Urology, 2020, 30, 720-725.	0.9	17
617	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. BJU International, 2021, 128, 280-289.	1.3	17
618	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 409-421.	0.8	17
619	Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. Journal of Urology, 2019, 201, 46-55.	0.2	17
620	Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. European Urology Oncology, 2022, 5, 403-411.	2.6	17
621	Carcinoma in situ of the Upper Urinary Tract Treated with Radical Nephroureterectomy – Results from a Multicenter Study. European Urology, 2008, 54, 961-963.	0.9	16
622	Head-to-head Comparison of Three Commonly Used Preoperative Tools for Prediction of Lymph Node Invasion at Radical Prostatectomy. Urology, 2011, 78, 1363-1367.	0.5	16
623	The Importance of Pelvic Lymph Node Dissection in the Elderly Population: Implications for Interpreting the 2010 National Comprehensive Cancer Network Practice Guidelines for Bladder Cancer Treatment. Journal of Urology, 2011, 185, 2078-2084.	0.2	16
624	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	1.2	16
625	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-967.	0.4	16
626	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.4	16
627	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	0.5	16
628	Multiparametric MRI of the prostate at 3T: limited value of 3D 1H-MR spectroscopy as a fourth parameter. World Journal of Urology, 2016, 34, 649-656.	1.2	16
629	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. BJU International, 2017, 119, 234-238.	1.3	16
630	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. International Journal of Urology, 2017, 24, 117-123.	0.5	16

#	ARTICLE	IF	CITATIONS
631	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 176-183.	0.9	16
632	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1399-1407.	1.2	16
633	The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 1247-1253.	1.2	16
634	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 307.e9-307.e14.	0.8	16
635	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e903-e908.	0.9	16
636	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018, 36, 51-57.	1.2	16
637	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 100-105.	2.0	16
638	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. <i>European Urology Oncology</i> , 2018, 1, 169-175.	2.6	16
639	Prostate biopsy. <i>Current Opinion in Urology</i> , 2018, 28, 354-359.	0.9	16
640	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. <i>BJU International</i> , 2019, 124, 1006-1013.	1.3	16
641	Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. <i>European Urology Focus</i> , 2020, 6, 298-304.	1.6	16
642	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
643	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	1.3	16
644	Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. <i>Current Opinion in Urology</i> , 2021, 31, 354-362.	0.9	16
645	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1587-1599.	1.0	16
646	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. <i>Current Oncology</i> , 2021, 28, 2881-2892.	0.9	16
647	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. <i>Canadian Urological Association Journal</i> , 2012, 6, 245-250.	0.3	16
648	Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics. <i>European Journal of Radiology</i> , 2022, 147, 110145.	1.2	16

#	ARTICLE	IF	CITATIONS
649	GENDER IS AN IMPORTANT PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PATIENT WITH TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2009, 181, 635.	0.2	15
650	Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner. <i>Journal of Urology</i> , 2011, 186, 2107-2114.	0.2	15
651	Biomarkers in personalised treatment of renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2012, 13, 751-752.	5.1	15
652	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1716-1724.	0.8	15
653	Highlights from the first symposium on upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 309-316.	0.8	15
654	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	0.8	15
655	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. <i>Translational Andrology and Urology</i> , 2016, 5, 720-734.	0.6	15
656	North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. <i>Prostate</i> , 2017, 77, 542-548.	1.2	15
657	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e421-e427.	0.9	15
658	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 1557-1570.	1.2	15
659	The impact of gender on oncologic outcomes of bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 279-285.	0.9	15
660	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 105-113.e2.	0.9	15
661	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. <i>Cancer Epidemiology</i> , 2019, 58, 83-88.	0.8	15
662	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e402-e409.	0.9	15
663	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
664	Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?. <i>European Journal of Radiology</i> , 2021, 142, 109829.	1.2	15
665	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
666	Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 2997-3004.	0.7	14

#	ARTICLE	IF	CITATIONS
667	Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. <i>World Journal of Urology</i> , 2015, 33, 1005-1013.	1.2	14
668	Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 96-104.	0.9	14
669	Construct, content and face validity of the camera handling trainer (CHT): a new E-BLUS training task for 30Å° laparoscope navigation skills. <i>World Journal of Urology</i> , 2016, 34, 479-484.	1.2	14
670	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e1-528.e5.	0.8	14
671	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	0.9	14
672	Role of quantitative computed tomography texture analysis in the prediction of adherent perinephric fat. <i>World Journal of Urology</i> , 2018, 36, 1635-1642.	1.2	14
673	Novel endoscopic visualization techniques for bladder cancer detection. <i>Current Opinion in Urology</i> , 2018, 28, 214-218.	0.9	14
674	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 577-583.	0.9	14
675	Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2018, 1, 283-291.	2.6	14
676	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 893-899.	0.8	14
677	Role of lasers in urology. <i>Photochemical and Photobiological Sciences</i> , 2019, 18, 295-303.	1.6	14
678	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. <i>Surgical Oncology</i> , 2019, 28, 208-213.	0.8	14
679	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 623-631.	0.5	14
680	Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?. <i>Translational Andrology and Urology</i> , 2019, 8, 85-93.	0.6	14
681	Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. <i>Current Treatment Options in Oncology</i> , 2019, 20, 40.	1.3	14
682	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	0.9	14
683	Enhanced Recovery after Radical Cystectomy. <i>Current Opinion in Urology</i> , 2019, 29, 227-238.	0.9	14
684	The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). <i>Clinical Genitourinary Cancer</i> , 2021, 19, 272.e1-272.e7.	0.9	14

#	ARTICLE	IF	CITATIONS
685	Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. <i>European Urology Focus</i> , 2020, 7, 566-573.	1.6	14
686	Catalog of exogenous risk factors for bladder carcinogenesis. <i>Current Opinion in Urology</i> , 2020, 30, 449-456.	0.9	14
687	Impact of systemic Immune-inflammatory Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	0.8	14
688	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773.	0.8	14
689	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1072-1089.	1.6	14
690	Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 350-359.	3.9	14
691	Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation. <i>Central European Journal of Urology</i> , 2016, 69, 366-369.	0.2	14
692	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 106.e11-106.e19.	0.8	14
693	EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY. <i>Journal of Urology</i> , 2009, 181, 629.	0.2	13
694	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. <i>International Urology and Nephrology</i> , 2013, 45, 1561-1567.	0.6	13
695	The impact of the ABO and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2015, 33, 1769-1776.	1.2	13
696	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. <i>Translational Andrology and Urology</i> , 2016, 5, 702-710.	0.6	13
697	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016, 196, 46-51.	0.2	13
698	Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. <i>Journal of Urology</i> , 2016, 195, 1120-1125.	0.2	13
699	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 151.e17-151.e23.	0.8	13
700	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. <i>Radiotherapy and Oncology</i> , 2018, 127, 318-325.	0.3	13
701	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≥50 years: a population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 71-77.	2.0	13
702	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	0.9	13

#	ARTICLE	IF	CITATIONS
703	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	0.9	13
704	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 54, 112-118.	0.8	13
705	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. Canadian Urological Association Journal, 2018, 12, E325-30.	0.3	13
706	Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. Minerva Urology and Nephrology, 2018, 70, 242-251.	1.3	13
707	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	1.0	13
708	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. World Journal of Urology, 2019, 37, 1305-1313.	1.2	13
709	A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery. Current Opinion in Urology, 2020, 30, 853-860.	0.9	13
710	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 537-544.	0.8	13
711	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	1.2	13
712	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU International, 2021, 127, 617-625.	1.3	13
713	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. Prostate, 2021, 81, 339-346.	1.2	13
714	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. European Urology Focus, 2022, 8, 491-497.	1.6	13
715	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102242.	3.4	13
716	Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?. BJU International, 2023, 131, 190-197.	1.3	13
717	Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. BJU International, 2012, 110, 961-966.	1.3	12
718	Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. European Urology, 2014, 66, 811-814.	0.9	12
719	Immune therapy meets precision medicine. Lancet Oncology, The, 2017, 18, 271-273.	5.1	12
720	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	1.2	12

#	ARTICLE	IF	CITATIONS
721	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. <i>Bladder Cancer</i> , 2017, 3, 161-169.	0.2	12
722	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 347-356.	1.5	12
723	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. <i>European Urology Oncology</i> , 2018, 1, 215-222.	2.6	12
724	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 101, 65-73.	0.6	12
725	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018, 101, 197-200.	0.6	12
726	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2019, 51, 2181-2188.	0.6	12
727	Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1459.	1.0	12
728	Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 2313-2324.	1.2	12
729	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2019, 33, 606-613.	1.1	12
730	Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 273-281.	0.8	12
731	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. <i>European Urology Focus</i> , 2019, 5, 381-388.	1.6	12
732	Aristolochic acid and its effect on different cancers in uro-oncology. <i>Current Opinion in Urology</i> , 2020, 30, 689-695.	0.9	12
733	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 547-556.	0.9	12
734	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 601.e17-601.e24.	0.8	12
735	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 59-66.	0.7	12
736	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 239-252.	1.6	12
737	Association between Inflammatory Potential of Diet and Bladder Cancer Risk: Results of 3 United States Prospective Cohort Studies. <i>Journal of Urology</i> , 2019, 202, 484-489.	0.2	12
738	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. <i>Translational Andrology and Urology</i> , 2017, 6, 1018-1026.	0.6	12

#	ARTICLE	IF	CITATIONS
739	A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. <i>BJU International</i> , 2012, 109, 1177-1182.	1.3	11
740	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. <i>Urology</i> , 2016, 88, 97-103.	0.5	11
741	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 386-393.	2.0	11
742	Oncologic outcomes after minimally invasive surgery for cT1 renal masses. <i>Current Opinion in Urology</i> , 2018, 28, 132-138.	0.9	11
743	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. <i>World Journal of Urology</i> , 2018, 36, 1417-1422.	1.2	11
744	Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. <i>Journal of Endourology</i> , 2018, 32, 701-709.	1.1	11
745	Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 695-703.	1.1	11
746	The evolving role of percutaneous biopsy in renal masses. <i>Current Opinion in Urology</i> , 2018, 28, 364-368.	0.9	11
747	Cost analysis of prostate cancer detection including the prostate health index (phi). <i>World Journal of Urology</i> , 2019, 37, 481-487.	1.2	11
748	Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. <i>International Journal of Urology</i> , 2019, 26, 487-492.	0.5	11
749	Salvage therapeutic strategies for bacillus Calmette-Guérin failure. <i>Current Opinion in Urology</i> , 2019, 29, 239-246.	0.9	11
750	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	1.6	11
751	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 129-137.e3.	0.9	11
752	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. <i>Cells</i> , 2020, 9, 1839.	1.8	11
753	Where do urologists stand in the era of novel coronavirus-2019 disease. <i>Current Opinion in Urology</i> , 2020, 30, 610-616.	0.9	11
754	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 602.e11-602.e19.	0.8	11
755	Sex- and age-related differences in the distribution of bladder cancer metastases. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 976-983.	0.6	11
756	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277.	1.6	11

#	ARTICLE	IF	CITATIONS
757	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	1.1	11
758	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	2.0	11
759	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 451-459.	2.6	11
760	Histologic Variants of Upper Tract Urothelial Carcinoma Do Not Affect Response to Adjuvant Chemotherapy After Radical Nephroureterectomy. <i>European Urology</i> , 2012, 62, e25-e26.	0.9	10
761	Contemporary Gender-Specific Outcomes in Germany After Radical Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , 2014, 15, 409.	1.0	10
762	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1411-1419.	1.2	10
763	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e21-33.e26.	0.8	10
764	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 460.e1-460.e8.	0.8	10
765	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e1-158.e6.	0.8	10
766	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1552-1556.	2.9	10
767	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 702-710.	0.8	10
768	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 123-129.	0.8	10
769	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 72-78.e4.	0.9	10
770	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. <i>World Journal of Urology</i> , 2020, 38, 121-128.	1.2	10
771	Conditional survival of patients with stage Iâ€“III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. <i>World Journal of Urology</i> , 2020, 38, 725-732.	1.2	10
772	Pathomics in urology. <i>Current Opinion in Urology</i> , 2020, 30, 823-831.	0.9	10
773	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	1.3	10
774	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1786-1793.	0.6	10

#	ARTICLE	IF	CITATIONS
775	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 39, 1961-1968.	1.2	10
776	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. Bladder Cancer, 2020, 6, 201-210.	0.2	10
777	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nursesâ€™ Health Study and Nursesâ€™ Health Study II. International Journal of Epidemiology, 2020, 49, 599-607.	0.9	10
778	Ureteral and urethral recurrence after radical cystectomy: a systematic review. Current Opinion in Urology, 2020, 30, 441-448.	0.9	10
779	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e610-e618.	0.9	10
780	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU International, 2021, 127, 528-537.	1.3	10
781	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e1-236.e7.	0.8	10
782	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)â€”do we still need contrast media?. European Radiology, 2021, 31, 3754-3764.	2.3	10
783	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 180-190.	0.8	10
784	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Nonâ€”clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	1.6	10
785	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	1.6	10
786	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World Journal of Urology, 2021, 39, 3771-3779.	1.2	10
787	Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Nonâ€”muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 109-112.	2.6	10
788	Adherent perinephric fat affects perioperative outcomes after partial nephrectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 636-646.	1.0	10
789	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Molecular Cancer, 2022, 21, 7.	7.9	10
790	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	1.0	10
791	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. International Urology and Nephrology, 2022, 54, 1521-1527.	0.6	10
792	Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in highâ€”grade non-muscle-invasive urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 491.e11-491.e19.	0.8	10

#	ARTICLE	IF	CITATIONS
793	Nomogram aids clinical decision making after radical cystectomy. <i>Nature Reviews Urology</i> , 2010, 7, 182-184.	1.9	9
794	Hospital and Surgical Caseload are Predictors of Comprehensive Surgical Treatment for Bladder Cancer: A Population Based Study. <i>Journal of Urology</i> , 2011, 186, 824-828.	0.2	9
795	Collaborative Research Networks as a Platform for Virtual Multidisciplinary, International Approach to Managing Difficult Clinical Cases: An Example from the Upper Tract Urothelial Carcinoma Collaboration. <i>European Urology</i> , 2012, 62, 943-945.	0.9	9
796	Can We Apply Nomograms Derived in the United States to European Patients? Yes, We Can!. <i>European Urology</i> , 2012, 61, 65-66.	0.9	9
797	Novel Biomarkers to Predict Response and Prognosis in Localized Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 225-233.	0.8	9
798	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	1.2	9
799	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e681-e688.	0.9	9
800	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol</i> 2017;71:447-61. <i>European Urology</i> , 2017, 71, e173-e174.	0.9	9
801	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2193-2199.	0.5	9
802	Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. <i>Current Opinion in Urology</i> , 2018, 28, 485-490.	0.9	9
803	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 578.e11-578.e19.	0.8	9
804	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e939-e945.	0.9	9
805	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. <i>Urologia Internationalis</i> , 2019, 102, 269-276.	0.6	9
806	Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1374.	1.8	9
807	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. <i>Cancer Epidemiology</i> , 2019, 59, 135-142.	0.8	9
808	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	1.2	9
809	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1127-1135.	1.2	9
810	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	0.9	9

#	ARTICLE	IF	CITATIONS
811	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , 2020, 31, 263-272.	0.8	9
812	Intravesical therapy for bladder cancer in the pandemic of Covid-19. <i>World Journal of Urology</i> , 2021, 39, 1313-1314.	1.2	9
813	Primary Ta high grade bladder tumors: Determination of the risk of progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 132.e7-132.e11.	0.8	9
814	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9
815	Radical Cystectomy vs. Multimodality Treatment in T2NOM0 Bladder Cancer: A Population-based, Age-matched Analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e264-e271.	0.9	9
816	Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society. <i>JMIR Research Protocols</i> , 2020, 9, e15363.	0.5	9
817	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 531-542.	3.9	9
818	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174.	1.2	9
819	A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
820	Genomics: a preview of genomic medicine. <i>BJU International</i> , 2008, 102, 1221-1227.	1.3	8
821	Preoperative chemotherapy for bladder cancer. <i>Cancer</i> , 2012, 118, 8-11.	2.0	8
822	The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?. <i>World Journal of Urology</i> , 2013, 31, 1369-1376.	1.2	8
823	Re: A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-stage Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 399-400.	0.9	8
824	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	0.8	8
825	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. <i>World Journal of Urology</i> , 2015, 33, 2087-2093.	1.2	8
826	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.2	8
827	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1189-1199.	1.5	8
828	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. <i>Urology</i> , 2017, 106, 119-124.	0.5	8

#	ARTICLE	IF	CITATIONS
829	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. Pathology and Oncology Research, 2018, 24, 575-581.	0.9	8
830	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	1.6	8
831	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. Journal of Endourology, 2018, 32, 621-629.	1.1	8
832	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e1153-e1162.	0.9	8
833	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e1-179.e7.	0.8	8
834	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. World Journal of Urology, 2020, 38, 1535-1544.	1.2	8
835	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages—A SEER-based Study. European Urology Focus, 2021, 7, 1332-1338.	1.6	8
836	The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Review of Clinical Pharmacology, 2020, 13, 707-720.	1.3	8
837	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. European Journal of Surgical Oncology, 2020, 46, 1347-1352.	0.5	8
838	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	0.8	8
839	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aNOMO Renal Cell Carcinoma Patients. European Urology Focus, 2022, 8, 191-199.	1.6	8
840	Differential Prognosis and Response of De novo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. Cancers, 2021, 13, 2496.	1.7	8
841	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. Current Opinion in Urology, 2021, 31, 297-303.	0.9	8
842	Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. Current Opinion in Urology, 2021, 31, 291-296.	0.9	8
843	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. Clinical Genitourinary Cancer, 2021, 19, e255-e263.	0.9	8
844	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. Surgical Oncology, 2021, 38, 101588.	0.8	8
845	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	1.3	8
846	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, .	1.3	8

#	ARTICLE	IF	CITATIONS
847	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. World Journal of Urology, 2022, 40, 1481-1488.	1.2	8
848	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	0.8	8
849	Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. Aging Male, 2022, 25, 62-66.	0.9	8
850	COMBINATION OF CELL CYCLE REGULATING BIO-MARKERS IMPROVES PROGNOSIS IN PATIENTS WITH ORGAN CONFINED UROTHELIAL CANCER AT RADICAL CYSTECTOMY. Journal of Urology, 2008, 179, 578-578.	0.2	7
851	Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomarkers in Medicine, 2008, 2, 165-180.	0.6	7
852	The effect of age on bladder cancer incidence, prognosis and therapy. Aging Health, 2010, 6, 649-659.	0.3	7
853	Management of upper urinary tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1955-1965.	1.1	7
854	Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. Journal of Urology, 2011, 185, 1112-1117.	0.2	7
855	Comprehensive handbook for developing a bladder cancer cystectomy database. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 812-826.	0.8	7
856	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. World Journal of Urology, 2016, 34, 105-112.	1.2	7
857	Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e9-113.e14.	0.8	7
858	Focal therapy of prostate cancer. Current Opinion in Urology, 2018, 28, 550-554.	0.9	7
859	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. BJU International, 2018, 122, 695-704.	1.3	7
860	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. European Urology Oncology, 2018, 1, 346-351.	2.6	7
861	Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. Canadian Urological Association Journal, 2018, 12, E338-44.	0.3	7
862	Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World Journal of Urology, 2019, 37, 165-172.	1.2	7
863	Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer. Immunotherapy, 2019, 11, 1083-1086.	1.0	7
864	Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e97-e103.	0.9	7

#	ARTICLE	IF	CITATIONS
865	What Is Better for Predicting Morbidity of Robotic Partial Nephrectomy? A Score or Your Clinical Judgement?. <i>European Urology Focus</i> , 2020, 6, 313-319.	1.6	7
866	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1067-1074.	1.6	7
867	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	0.8	7
868	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	1.2	7
869	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. <i>European Journal of Surgical Oncology</i> , 2021, 47, 463-469.	0.5	7
870	Making a case against focal therapy for intermediate-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 719-728.	1.2	7
871	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 75.e17-75.e25.	0.8	7
872	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 15-33.	0.8	7
873	Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. <i>Cancers</i> , 2021, 13, 244.	1.7	7
874	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	0.9	7
875	The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. <i>Current Opinion in Urology</i> , 2021, 31, 315-323.	0.9	7
876	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479.	0.8	7
877	Tissue-based molecular markers for bladder cancer. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2010, 62, 241-58.	3.9	7
878	Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 381-95.	3.9	7
879	Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. <i>Prostate</i> , 2022, 82, 740-750.	1.2	7
880	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Cancers</i> , 2022, 14, 1222.	1.7	7
881	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	1.6	7
882	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.2	7

#	ARTICLE	IF	CITATIONS
883	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	2.0	7
884	Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 380.e19-380.e27.	0.8	7
885	Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. <i>Journal of Surgical Oncology</i> , 2022, 126, 830-837.	0.8	7
886	Perspectives on Prostate Cancer Biomarkers. <i>European Urology</i> , 2008, 54, 8-10.	0.9	6
887	Impact of Statin Use on Oncologic Outcomes of Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1134-1135.	0.9	6
888	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. <i>European Urology Focus</i> , 2015, 1, 75-81.	1.6	6
889	Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. <i>Translational Andrology and Urology</i> , 2016, 5, 711-719.	0.6	6
890	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	0.8	6
891	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 528.e7-528.e13.	0.8	6
892	Tissue biomarkers in nonmuscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 584-590.	0.9	6
893	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. <i>Journal of Surgical Oncology</i> , 2019, 120, 1266-1275.	0.8	6
894	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1253-1259.	0.5	6
895	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e541-e548.	0.9	6
896	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	0.8	6
897	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 117-128.e5.	0.9	6
898	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 701-710.	0.9	6
899	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	1.2	6
900	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	0.8	6

#	ARTICLE	IF	CITATIONS
901	Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study. <i>Nutrition and Cancer</i> , 2021, 73, 2665-2670.	0.9	6
902	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1143-1156.	1.6	6
903	Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 542-546.	0.9	6
904	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. <i>Current Opinion in Urology</i> , 2020, 30, 584-593.	0.9	6
905	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. <i>World Journal of Urology</i> , 2021, 39, 813-822.	1.2	6
906	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 31-36.	0.7	6
907	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	2.0	6
908	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e11-785.e17.	0.8	6
909	Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2489.	1.7	6
910	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e7-788.e13.	0.8	6
911	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. <i>European Urology Oncology</i> , 2022, 5, 138-145.	2.6	6
912	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	1.3	6
913	Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. <i>Translational Andrology and Urology</i> , 2021, 10, 4051-4061.	0.6	6
914	E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUP. <i>Journal of Urology</i> , 2001, , 1473-1479.	0.2	6
915	Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. <i>Oncotarget</i> , 2018, 9, 16197-16204.	0.8	6
916	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	6
917	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 610-615.	1.3	6
918	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	0.7	6

#	ARTICLE	IF	CITATIONS
919	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.0	6
920	Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 722-725.	2.6	6
921	Novel Urinary Markers for Detection of Bladder Cancer—Are we Failing?. <i>Journal of Urology</i> , 2014, 191, 9-10.	0.2	5
922	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	0.2	5
923	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e223-e228.	0.9	5
924	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. <i>Canadian Urological Association Journal</i> , 2019, 14, E84-E93.	0.3	5
925	Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. <i>European Urology</i> , 2019, 75, 695-696.	0.9	5
926	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 774-783.	0.8	5
927	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e793-e801.	0.9	5
928	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1631-1637.	1.2	5
929	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. <i>European Urology Focus</i> , 2020, 6, 1213-1219.	1.6	5
930	Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2020, 38, 1525-1533.	1.2	5
931	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 260-268.	2.0	5
932	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e450-e456.	0.9	5
933	The role of taxane-based chemotherapy in the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 527-533.	0.9	5
934	Rates of other-cause mortality after radical cystectomy are decreasing over time—A population-based analysis over two decades. <i>Journal of Surgical Oncology</i> , 2020, 121, 1329-1336.	0.8	5
935	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 143-152.	1.3	5
936	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	1.0	5

#	ARTICLE	IF	CITATIONS
937	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	0.6	5
938	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207400.	1.0	5
939	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275.	0.9	5
940	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. <i>Current Opinion in Urology</i> , 2021, 31, 324-331.	0.9	5
941	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1707-1713.	1.0	5
942	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 789.e9-789.e17.	0.8	5
943	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	0.9	5
944	Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS502-TPS502.	0.8	5
945	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. , 2017, 37, 5747-5753.		5
946	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 880-888.	0.6	5
947	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology " Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35.	0.8	5
948	The placebo and nocebo effects in functional urology. <i>Nature Reviews Urology</i> , 2022, 19, 171-189.	1.9	5
949	Re: Tamsulosin, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>European Urology</i> , 2009, 55, 250-252.	0.9	4
950	Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from a Large Multicenter International Collaborative Study. <i>European Urology</i> , 2013, 63, 404-405.	0.9	4
951	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 676-681.	0.8	4
952	Re: Global Effects of Smoking, of Quitting, and of Taxing Tobacco. <i>European Urology</i> , 2014, 66, 176-178.	0.9	4
953	Prostate Cancer Risk Estimation Tool Use by Members of the American Urological Association: A Survey Based Study. <i>Journal of Urology</i> , 2015, 193, 1933-1937.	0.2	4
954	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016, 34, 1155-1161.	1.2	4

#	ARTICLE	IF	CITATIONS
955	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq1 1 0.784304rgBT /Overlock 10	0.8	4
956	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	0.8	4
957	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 672.e1-672.e6.	0.8	4
958	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e619-e627.	0.9	4
959	Molecularly-driven precision medicine for advanced bladder cancer. World Journal of Urology, 2018, 36, 1749-1757.	1.2	4
960	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	0.8	4
961	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. Oncology Letters, 2019, 18, 57-62.	0.8	4
962	A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). Urologic Oncology: Seminars and Original Investigations, 2019, 37, 577.e1-577.e7.	0.8	4
963	Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. Expert Review of Anticancer Therapy, 2019, 19, 503-513.	1.1	4
964	Transfer of Knowledge in Urology: A Case Study of Jacob Eduard Polak (1818â€“1891) and the Introduction of Contemporary Techniques of Lithotomy and Lithotripsy from Vienna to Persia in the Mid-19th Century: A New Analysis of Scientific Papers from the 19th Century. Urologia Internationalis, 2019, 102, 1-12.	0.6	4
965	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. World Journal of Urology, 2019, 37, 1329-1337.	1.2	4
966	Risk stratification for upper tract urinary carcinoma. Translational Andrology and Urology, 2020, 9, 1799-1808.	0.6	4
967	Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study. Nutrition and Cancer, 2021, 73, 2538-2545.	0.9	4
968	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. Scandinavian Journal of Urology, 2020, 54, 52-57.	0.6	4
969	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). Urologic Oncology: Seminars and Original Investigations, 2020, 38, 423-432.	0.8	4
970	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 369.e9-369.e17.	0.8	4
971	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate, 2021, 81, 765-771.	1.2	4
972	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4

#	ARTICLE	IF	CITATIONS
973	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
974	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	0.8	4
975	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 962-970.	1.0	4
976	Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers. <i>Translational Andrology and Urology</i> , 2018, 7, S753-S755.	0.6	4
977	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	1.2	4
978	Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. <i>European Urology Focus</i> , 2022, 8, 1622-1626.	1.6	4
979	Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	4
980	Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1841-1843.	0.8	3
981	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. <i>Current Geriatrics Reports</i> , 2014, 3, 42-47.	1.1	3
982	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.	0.8	3
983	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. <i>International Journal of Urology</i> , 2018, 25, 929-936.	0.5	3
984	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 389-394.	0.9	3
985	Second line immune checkpoint inhibition in urothelial cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 414-420.	0.6	3
986	4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. <i>PLoS ONE</i> , 2019, 14, e0225673.	1.1	3
987	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 97-103.	1.6	3
988	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. <i>European Urology</i> , 2020, 77, 1-2.	0.9	3
989	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	0.8	3
990	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 567-574.	0.6	3

#	ARTICLE	IF	CITATIONS
991	Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. <i>European Urology Focus</i> , 2022, 8, 447-456.	1.6	3
992	Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. <i>Current Opinion in Urology</i> , 2021, 31, 220-225.	0.9	3
993	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	1.0	3
994	Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2087-2093.	1.0	3
995	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.2	3
996	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. <i>International Journal of Urology</i> , 2021, 28, 1247-1252.	0.5	3
997	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , 2020, 73, 407-415.	0.2	3
998	Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 195.e1-195.e8.	0.9	3
999	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	0.9	3
1000	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	1.6	3
1001	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. <i>Scandinavian Journal of Urology</i> , 2022, 56, 85-93.	0.6	3
1002	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 1489-1496.	1.2	3
1003	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 708-717.	1.8	3
1004	Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. <i>Prostate</i> , 2022, 82, 687-694.	1.2	3
1005	Prognostic impact of insulin-like growth factor-1 and its binding proteins, insulin-like growth factor-1 binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	0.5	3
1006	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
1007	Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1332-1337.	1.6	3
1008	Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. <i>World Journal of Urology</i> , 0, , .	1.2	3

#	ARTICLE	IF	CITATIONS
1009	Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. International Urology and Nephrology, 2022, 54, 2521-2528.	0.6	3
1010	The Impact of Surgical Waiting Time on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 4007.	1.0	3
1011	Re: Timing of Androgen Deprivation Therapy and Its Impact on Survival after Radical Prostatectomy: A Matched Cohort Study. European Urology, 2009, 55, 245-246.	0.9	2
1012	Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. European Urology, 2014, 66, 386-387.	0.9	2
1013	Electronic Cigarettes: A Wolf in Sheep's Clothing. European Urology, 2017, 71, 924-925.	0.9	2
1014	Gender Differences in Bladder and Kidney Cancers. , 2017, , 603-610.		2
1015	The effect of race on survival after local therapy in metastatic prostate cancer patients. Canadian Urological Association Journal, 2018, 13, 175-181.	0.3	2
1016	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer, 2020, 18, 35-44.e1.	0.9	2
1017	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. European Urology Open Science, 2020, 19, 16-19.	0.2	2
1018	An up-to-date catalogue of urinary markers for the management of prostate cancer. Current Opinion in Urology, 2020, Publish Ahead of Print, 684-688.	0.9	2
1019	Novel technologies that change the diagnostic and treatment paradigm in urology. Current Opinion in Urology, 2020, 30, 475-476.	0.9	2
1020	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. Current Opinion in Urology, 2020, 30, 457-466.	0.9	2
1021	Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. Prostate, 2021, 81, 1055-1063.	1.2	2
1022	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	1.3	2
1023	Editorial: Lower urinary tract symptoms, benign prostate hyperplasia and beyond. Current Opinion in Urology, 2021, 31, 437.	0.9	2
1024	The Consequences of Inadvertent Radical Nephrectomy in the Treatment of Upper Tract Urothelial Carcinoma. Urology, 2021, 154, 127-135.	0.5	2
1025	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. Prostate, 2022, 82, 120-131.	1.2	2
1026	Fighting the "tobacco epidemic" – A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 793-796.	0.8	2

#	ARTICLE	IF	CITATIONS
1027	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25.	0.8	2
1028	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. <i>Central European Journal of Urology</i> , 2021, 74, 484-490.	0.2	2
1029	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	1.2	2
1030	Ischemic Priapism in a 12 Year Old Patient Associated With Coronavirus Disease 2019 (COVID-19): A Case Report. <i>Urology</i> , 2022, 165, 316-318.	0.5	2
1031	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	0.4	2
1032	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. <i>Surgical Oncology</i> , 2022, 42, 101783.	0.8	2
1033	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. <i>Prostate</i> , 2022, 82, 1210-1218.	1.2	2
1034	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. <i>European Urology Open Science</i> , 2022, 41, 74-80.	0.2	2
1035	Does Low-Risk Prostate Cancer Detection Change With Repeat Biopsies?. <i>European Urology</i> , 2012, 61, 230-231.	0.9	1
1036	Blood-Based Tumor Markers for Prostate Cancer. , 2013, , 73-84.		1
1037	Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. <i>European Urology</i> , 2013, 64, 683-684.	0.9	1
1038	Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. <i>BJU International</i> , 2014, 113, 516-517.	1.3	1
1039	Incorporating biomarker research in a real-world setting: Challenges of a prophecy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 219-221.	0.8	1
1040	There Are Cooler Ways to Die Than Smoking: Urologists of the World, Unite Against This Health Care Tragedy. <i>European Urology Focus</i> , 2015, 1, 1-2.	1.6	1
1041	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor: Are: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>Eur Urol.</i> In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038 . <i>European Urology</i> , 2015, 68, e104-e105.	0.9	1
1042	Building bridges in urothelial carcinoma to face common challenges. <i>Translational Andrology and Urology</i> , 2016, 5, 745-748.	0.6	1
1043	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>European Urology</i> , 2016, 70, 205-206.	0.9	1
1044	The effect of ABO and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 671.e17-671.e23.	0.8	1

#	ARTICLE	IF	CITATIONS
1045	MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
1046	Robot-assisted partial nephrectomy. <i>Current Opinion in Urology</i> , 2018, 28, 123-131.	0.9	1
1047	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e59-e65.	0.9	1
1048	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2019, , 291-301.		1
1049	Neoadjuvant therapy in urothelial cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 329-333.	0.3	1
1050	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. <i>European Urology Oncology</i> , 2019, 4, 663-669.	2.6	1
1051	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e98-e99.	0.9	1
1052	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2019, 14, E173-E179.	0.3	1
1053	Prognostic models to help predict patient responses to intravesical immunotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 243-251.	0.4	1
1054	Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 MO non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. <i>International Journal of Urology</i> , 2020, 27, 402-407.	0.5	1
1055	Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2021, 79, 163-164.	0.9	1
1056	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
1057	Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. <i>Journal of Clinical Medicine</i> , 2021, 10, 1055.	1.0	1
1058	Difference in Incontinence Pad Use between Patients after Radical Prostatectomy and Cancer-Free Population with Subgroup Analysis for Open vs. Minimally Invasive Radical Prostatectomy: A Descriptive Analysis of Insurance Claims-Based Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6891.	1.2	1
1059	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 917-929.	1.0	1
1060	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1147.	1.1	1
1061	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. <i>International Urology and Nephrology</i> , 2021, 54, 81.	0.6	1
1062	Recent pharmacological approaches for the treatment of renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 187-195.	1.3	1

#	ARTICLE	IF	CITATIONS
1063	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 389.e1-389.e7.	0.9	1
1064	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
1065	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.4	1
1066	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. <i>European Urology Open Science</i> , 2022, 40, 117-124.	0.2	1
1067	Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
1068	Re: Pathologic Stage T2a and T2b Prostate Cancer in the Recent Prostate-Specific Antigen Era: Implications for Unilateral Ablative Therapy. <i>European Urology</i> , 2009, 56, 573-575.	0.9	0
1069	Reply to Pascal Mouracade's Letter to the Editor re: Thomas F. Chromecki, Eugene K. Cha, Harun Fajkovic, et al. The Impact of Tumor Multifocality on Outcomes in Patients Treated with Radical Nephroureterectomy. <i>Eur Urol</i> 2012;61;245-253. <i>European Urology</i> , 2012, 62, e77-e78.	0.9	0
1070	Renal Cancer Therapy: Going Forward by Going Backward?. <i>European Urology</i> , 2013, 63, 890-891.	0.9	0
1071	Bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 483-486.	0.9	0
1072	Adrenal Lesions: Progress on All Fronts. <i>European Urology Focus</i> , 2016, 1, 215-216.	1.6	0
1073	Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. <i>European Urology</i> , 2017, 72, 474-475.	0.9	0
1074	Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 1025-1026.	0.9	0
1075	Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 471-472.	0.9	0
1076	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 74, 680-681.	0.9	0
1077	The Role of Urologist. , 2018, , 101-112.		0
1078	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2018, , 1-11.		0
1079	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-328. <i>European Urology</i> , 2019, 75, e95.	0.9	0
1080	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 132-133.	0.9	0

#	ARTICLE	IF	CITATIONS
1081	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer and Prostatic Diseases, 2021, 24, 439-447.	2.0	0
1082	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchiâ€™s Letter to the Editor re: Francesco Soria, Marco Moschini, David Dâ€™Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233â€“9. European Urology Focus, 2021, , .	1.6	0
1083	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly â€“An International Multicenter Study. Bladder Cancer, 2021, 7, 173-185.	0.2	0
1084	Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5065-5065.	0.8	0
1085	Äœber Exzellenz und Reputation in Medizin und Urologie. , 2021, , 67-94.		0
1086	Increased risk of postoperative inâ€‘hospital complications after radical prostatectomy in patients with prior organ transplant. Prostate, 2021, 81, 1294-1302.	1.2	0
1087	Risk Stratification of Upper Tract Urothelial Carcinoma for Kidney-Sparing Surgery. , 2021, , 387-402.		0
1088	Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. , 2015, , 91-117.		0
1089	Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma. Translational Andrology and Urology, 2016, 5, 633-635.	0.6	0
1090	Prognostic Factors and Predictive Tools in Upper Tract Urothelial Carcinoma. , 2018, , 15-32.		0
1091	Exploring the molecular basis of sexual dimorphism in bladder cancer. Nature Reviews Urology, 2020, 17, 487-488.	1.9	0
1092	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.2	0
1093	Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-GuÃ©rin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR) Tj ETQq1 1 0.7814 rgBT /Overlo	0.43	0
1094	Nonmuscle-invasive bladder cancer, old problems, new insights. Current Opinion in Urology, 2022, 32, 352-357.	0.9	0